Perspectives on the treatment of malignant pleural mesothelioma

SM Janes, D Alrifai, DA Fennell - New England Journal of …, 2021‏ - Mass Medical Soc
Mesothelioma Most mesotheliomas originate in the pleura and are due to asbestos
exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality …

ERS/EACTS statement on the management of malignant pleural effusions

AC Bibby, P Dorn, I Psallidas, JM Porcel… - European journal of …, 2019‏ - academic.oup.com
Malignant pleural effusions (MPE) are a common pathology, treated by respiratory
physicians and thoracic surgeons alike. In recent years, several well-designed randomized …

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

S Popat, P Baas, C Faivre-Finn, N Girard… - Annals of …, 2022‏ - annalsofoncology.org
Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than
females and is attributed to historical differences in exposures with world-standardised …

CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts

I Boutron, DG Altman, D Moher, KF Schulz… - Annals of internal …, 2017‏ - acpjournals.org
Incomplete and inadequate reporting is an avoidable waste that reduces the usefulness of
research. The CONSORT (Consolidated Standards of Reporting Trials) Statement is an …

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

E Lim, D Waller, K Lau, J Steele, A Pope… - The Lancet …, 2024‏ - thelancet.com
Background Extended pleurectomy decortication for complete macroscopic resection for
pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study …

[HTML][HTML] ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

A Scherpereel, I Opitz, T Berghmans… - European …, 2020‏ - publications.ersnet.org
The European Respiratory Society (ERS)/European Society of Thoracic Surgeons
(ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for …

Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline

HL Kindler, N Ismaila, SG Armato III… - Journal of Clinical …, 2018‏ - ascopubs.org
Purpose To provide evidence-based recommendations to practicing physicians and others
on the management of malignant pleural mesothelioma. Methods ASCO convened an …

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

AC Bibby, S Tsim, N Kanellakis, H Ball… - European …, 2016‏ - publications.ersnet.org
Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface,
predominantly caused by prior asbestos exposure. There is a global epidemic of malignant …

Interventions for the management of malignant pleural effusions: a network meta‐analysis

A Dipper, HE Jones, R Bhatnagar… - Cochrane Database …, 2020‏ - cochranelibrary.com
Background Malignant pleural effusion (MPE) is a common problem for people with cancer
and usually associated with considerable breathlessness. A number of treatment options are …

[HTML][HTML] Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P Baas, D Fennell, KM Kerr, PE Van Schil, RL Haas… - Annals of oncology, 2015‏ - Elsevier
Malignant pleural mesothelioma (MPM) is considered to be a relatively rare tumour. In Great
Britain, the incidence in males is 3.4/100 000, in France it is 2.3/100 000 and in the …